Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (8667)	2/10/1999 10:50:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Bluegas, what is all the hot air about? If Neuprex is really effective the only way it will get to market is if it is approved, by the F.D.A. and the Corresponding authorities in the E.C. Statistical significance must be demonstrated as you know better than I. I remain convinced that using a mortality target was probably the quickest way to the trial over. If a target had not been agreed to we might have been looking at a requirement for total accruals to reach at least 500. The famous last paragraph!! "The Bro-Taf health authority says it has been unable to find any link between Mrs James's illness and the other victims and that it is treating it as an "isolated" infection. But it was disclosed yesterday that Joyce Davies, 66, who died on January 30, has grandchildren at the school where Mrs James taught." If it was an isolated case they don't give out antibiotics to everyone a person might have had contact with but if an "epidemic" exist they do. It appears the case was not isolated. This is what is being investigated. Frankly I think they consider cases isolated when they can't identify another person as a source of infection.And since most of carry the germs who's to say where one caught it.